PGI7 EVALUATION OF LIVER OUTCOMES RELATIVE TO USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN REAL-WORLD POPULATIONS DIAGNOSED WITH TYPE II DIABETES (T2DM) AND NASH/NAFLD OR AT RISK OF NASH

To assess effect of GLP1a and/or SGLT2i on development of advanced liver disease in T2DM patients with NASH/NAFLD or at risk of NASH. Data collected from a proprietary US EMR database were limited to adult T2DM (ICD10 E11. 9) patients diagnosed with NASH/NAFLD (ICD10 K76, 75.81) or with a risk profile of [Age >50 + ALT >30 U/L + BMI >30] and without viral hepatitis or evidence of alcohol abuse. Index date was the first calculable FIB4 between...